Loading
FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Skin cancer, Lung cancer and 2 more.
May function as an inhibitor of the B-cell receptor signalling. May function in the B-cell-mediated immune response.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.39, genetic association 0.00, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Pancreatic Adenocarcinoma.
In plain words · FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Skin cancer, Lung cancer and 2 more.
FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Skin cancer, Lung cancer and 2 more.
May function as an inhibitor of the B-cell receptor signalling. May function in the B-cell-mediated immune response.
No product in this corpus aims at FCRL4 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2001. Earliest sequence paper UniProt cites for the protein: Hatzivassiliou et al, Immunity, 2001, "IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy". Source.
Sources: HGNC HGNC:18507 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96PJ5 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000163518 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: melanoma 0.55, skin cancer 0.56, breast cancer 0.51, lung cancer 0.54 (GraphQL API, CC0)); IntOGen FCRL4 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
May function as an inhibitor of the B-cell receptor signalling. May function in the B-cell-mediated immune response. Location: Cell membrane (UniProt). Locus 1q23.1 (HGNC).
Query for this target: (TITLE:"FCRL4" OR ABSTRACT:"FCRL4" OR TITLE:"Fc receptor like 4" OR ABSTRACT:"Fc receptor like 4" OR TITLE:"Fc receptor-like protein 4" OR ABSTRACT:"Fc receptor-like protein 4" OR TITLE:"FCRH4" OR ABSTRACT:"FCRH4" OR TITLE:"IRTA1" OR ABSTRACT:"IRTA1" OR TITLE:"IGFP2" OR ABSTRACT:"IGFP2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCRL4, not a curated reading list.